Study identifier:D8750C00002
ClinicalTrials.gov identifier:NCT06132841
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants with Overweight or Obesity
Healthy Participants
Phase 1
Yes
AZD6234, Placebo
All
76
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 Participants will receive repeated doses of AZD6234 or placebo via SC injection | Drug: AZD6234 Participants will receive repeated doses of AZD6234 as a solution via SC Drug: Placebo Participants will receive matching volumes of the placebo as a solution via SC |
Experimental: Cohort 2 Participants will receive repeated doses of AZD6234 or placebo via SC injection | Drug: AZD6234 Participants will receive repeated doses of AZD6234 as a solution via SC Drug: Placebo Participants will receive matching volumes of the placebo as a solution via SC |
Experimental: Cohort 3 Japanese participants will receive repeated doses of AZD6234 or placebo via SC injection | Drug: AZD6234 Participants will receive repeated doses of AZD6234 as a solution via SC Drug: Placebo Participants will receive matching volumes of the placebo as a solution via SC |